Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the ...

Zscaler has outperformed most growth stocks in 2024, rising nearly 20% year to date, driven in part by a recent beat and ...

The eurozone economy grew a little more than previously estimated at the end of last year thanks to ... 0.2% on quarter in the fourth quarter of 2024 across the 20 nations that share the euro ...

2024. ART26.12: Phase I study is on track for completion in Q2 2025. ART27.13: Initial data from the Phase 2 CAReS trial anticipated by the end of Q2 2025. ART12.11: Substantial progress has been ...

VIKTORIA-2 Phase 3 remains on track to enroll its first patient in Q2 2025 Presented encouraging preliminary overall survival ...